25 related articles for article (PubMed ID: 10956389)
1. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.
Balasubramanian A; John T; Asselin-Labat ML
Biochem Soc Trans; 2022 Apr; 50(2):825-837. PubMed ID: 35343573
[TBL] [Abstract][Full Text] [Related]
2. miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2.
Lu C; Peng K; Guo H; Ren X; Hu S; Cai Y; Han Y; Ma L; Xu P
Oncol Lett; 2018 Sep; 16(3):3150-3156. PubMed ID: 30127908
[TBL] [Abstract][Full Text] [Related]
3. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development.
Yavorski JM; Blanck G
Mol Clin Oncol; 2017 Dec; 7(6):1119-1121. PubMed ID: 29285385
[TBL] [Abstract][Full Text] [Related]
4. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.
Cui L; Deng Y; Rong Y; Lou W; Mao Z; Feng Y; Xie D; Jin D
Tumour Biol; 2012 Feb; 33(1):247-55. PubMed ID: 22119988
[TBL] [Abstract][Full Text] [Related]
5. Mutations and regulatory anomalies effecting tumor cell immune functions.
Blanck G
Cancer Immunol Immunother; 2004 Jan; 53(1):1-16. PubMed ID: 13680191
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel co-repressor molecules for Interferon Regulatory Factor-2.
Childs KS; Goodbourn S
Nucleic Acids Res; 2003 Jun; 31(12):3016-26. PubMed ID: 12799427
[TBL] [Abstract][Full Text] [Related]
7. A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.
Nehyba J; Hrdlicková R; Burnside J; Bose HR
Mol Cell Biol; 2002 Jun; 22(11):3942-57. PubMed ID: 11997525
[TBL] [Abstract][Full Text] [Related]
8. IRF regulation of HIV-1 long terminal repeat activity.
Battistini A; Marsili G; Sgarbanti M; Ensoli B; Hiscott J
J Interferon Cytokine Res; 2002 Jan; 22(1):27-37. PubMed ID: 11846973
[TBL] [Abstract][Full Text] [Related]
9. The Transcriptional Co-factor IRF2BP2: A New Player in Tumor Development and Microenvironment.
Pastor TP; Peixoto BC; Viola JPB
Front Cell Dev Biol; 2021; 9():655307. PubMed ID: 33996817
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor-2 point mutations in human pancreatic tumors.
Xi H; Blanck G
Int J Cancer; 2000 Sep; 87(6):803-8. PubMed ID: 10956389
[TBL] [Abstract][Full Text] [Related]
11. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2.
Xi H; Eason DD; Ghosh D; Dovhey S; Wright KL; Blanck G
Oncogene; 1999 Oct; 18(43):5889-903. PubMed ID: 10557076
[TBL] [Abstract][Full Text] [Related]
12. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2.
Xi H; Goodwin B; Shepherd AT; Blanck G
Oncogene; 2001 Jul; 20(31):4219-27. PubMed ID: 11464288
[TBL] [Abstract][Full Text] [Related]
13. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1.
Xi H; Blanck G
Mol Immunol; 2003 Jan; 39(11):677-84. PubMed ID: 12493643
[TBL] [Abstract][Full Text] [Related]
14. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
Dong Y; Rohn WM; Benveniste EN
J Immunol; 1999 Apr; 162(8):4731-9. PubMed ID: 10202014
[TBL] [Abstract][Full Text] [Related]
15. Cloning of an interferon regulatory factor 2 isoform with different regulatory ability.
Koenig Merediz SA; Schmidt M; Hoppe GJ; Alfken J; Meraro D; Levi BZ; Neubauer A; Wittig B
Nucleic Acids Res; 2000 Nov; 28(21):4219-24. PubMed ID: 11058120
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
